Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-12-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercell lungnon smallsmall celltransplantation
  Phrases that lowered it: participantsulnpatients whobodydays prior
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 27.7% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.1% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor's past trials: 1452 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 11211 (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer NCT03212469 · started 2017 · scored riskier than 99% of active trials completed
• Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC NCT04786093 · started 2021 · scored riskier than 96% of active trials terminated
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) NCT06083454 · started 2023 · scored riskier than 41% of active trials terminated
• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy NCT04372927 · started 2021 · scored riskier than 87% of active trials terminated
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC NCT04163432 · started 2020 · scored riskier than 89% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.